# A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma

> **NCT00315731** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 15 (actual)

## Conditions studied

- Lymphoma, Follicular

## Interventions

- **BIOLOGICAL:** Follicular Lymphoma

## Key facts

- **NCT ID:** NCT00315731
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03-31
- **Primary completion:** 2006-12-04
- **Final completion:** 2013-06-30
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00315731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00315731, "A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00315731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*